RxDoctor Payments Data

Niraj Parekh

Interventional Cardiology · Riverside, CANPI 1043416498

Payments from drug & device makers

$89,627in general payments, 2019–2025

Across 740 payments — averaging $121.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$31K
  • Shockwave Medical, Inc$24K
  • Abbott$18K
  • Medtronic$7K
  • Boston Scientific$3K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
  • plus $5K from 36 others

What the payments were for

  • Consulting fees$28,30032%
  • Speaking & faculty fees$34,92539%
  • Travel & lodging$2,5103%
  • Food & beverage$23,89327%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$89,627 in reported general payments places this provider in the 80th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$505,230
Medicare patients
867
Services billed
4,624

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban594$688,453
EntrestoSacubitril/Valsartan56$75,840
XareltoRivaroxaban70$69,863
BrilintaTicagrelor42$29,953
FarxigaDapagliflozin Propanediol16$21,689
JardianceEmpagliflozin17$18,523
MultaqDronedarone Hcl14$18,148
ClopidogrelClopidogrel Bisulfate734$8,861
Amiodarone Hcl136$3,892
Metoprolol Succinate254$3,428
Diltiazem 12hr ErDiltiazem Hcl11$3,127
Ranolazine ErRanolazine35$2,400
Atorvastatin Calcium244$2,354
Metoprolol Tartrate210$1,488
Carvedilol155$1,347

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$448$688,453594 claims
NovartisEntresto$451$75,84056 claims
Johnson & JohnsonXarelto$244$69,86370 claims
AstraZenecaBrilinta, Farxiga$71$51,64258 claims
Sanofi-aventis U.S. LLCMultaq$74$18,14814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Riverside

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →